Skip to main content
. 2010 Jan 7;49(4):697–705. doi: 10.1093/rheumatology/kep423

Table 4.

Predictors of higher EULAR response and disease remission in PsA cohort at 6 months

Variable Higher EULAR response, OR (95% CI) Disease remission, OR (95% CI)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Demographic variables
    Age at start of therapy 0.98* (0.96, 0.99) 0.97* (0.95, 0.99) 0.97* (0.95, 0.99) 0.96* (0.94, 0.99)
    Female 0.49* (0.35, 0.70) 0.51* (0.34, 0.78) 0.37* (0.25, 0.55) 0.34* (0.21, 0.57)
    Smoking (yes/no) 0.96 (0.68, 1.36) 1.07 (0.71, 1.59) 0.76 (0.51, 1.14) 0.74 (0.45, 1.20)
    Baseline co-morbiditya (yes/no) 0.88 (0.60, 1.29) 0.83 (0.53, 1.30) 0.77 (0.51, 1.16) 0.64 (0.38, 1.06)
Disease variables
    Baseline DAS-28 1.01 (0.99, 1.02) 0.99 (0.98, 1.02) 0.99 (0.98, 1.01) 0.99 (0.96, 1.02)
    Baseline HAQ 0.78* (0.62, 0.98) 0.85 (0.66, 1.08) 0.78 (0.59, 1.03) 0.85 (0.63, 1.15)
    Disease duration (years) 1.01 (0.99, 1.03) 1.02 (0.99, 1.04) 0.99 (0.97, 1.02) 1.00 (0.97, 1.04)
    Inflammationb 0.54* (0.30, 0.96) 0.54* (0.31, 0.97)
    TJC 1.00 (0.98, 1.03) 0.97 (0.95, 1.00)
    SJC 1.01 (0.99, 1.05) 0.99 (0.95, 1.02)
Therapeutic variables: concurrent use of
    DMARDs 1.31 (0.42, 4.06) 0.82 (0.19, 3.55) 0.42 (0.09, 1.93) 0.44 (0.05, 4.18)
    Steroids 0.48* (0.31, 0.74) 0.45* (0.28, 0.72) 0.57 (0.32, 1.01) 0.55 (0.29, 1.02)
Biological therapy: etanercept is the reference category
    Infliximab 0.55 (0.37, 1.82) 0.60 (0.38, 1.95) 0.57 (0.35, 1.94) 0.69 (0.39, 1.22)
    Adalimumab 1.01 (0.63, 1.63) 0.81 (0.44, 1.49) 1.16 (0.67, 1.99) 0.97 (0.46, 2.04)

*P < 0.05.

aIncludes any of hypertension, angina, ischemic heart disease, stroke, pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, diabetes, thyroid disease, peptic ulcers, hepatic disease, renal disease, demyelinating disease, epilepsy, depression, TB and cancer. bInflammation (CRP > 20 mg/l or ESR > 28 mm/h). SJC: swollen joint count; TJC: tender joint count.